Nuwellis, Inc. has been awarded U.S. Patent No. 12,678,592 for its Dual Lumen Catheter, a technology designed to enhance extracorporeal therapies such as ultrafiltration and dialysis. Issued on July 14, 2026, by the U.S. Patent and Trademark Office (USPTO), the patent strengthens the company's intellectual property portfolio. The device features a reinforcing stainless-steel coil to maintain patency under negative pressure, addressing a common clinical challenge where blood pumps cause catheter collapse. This innovation is intended to improve blood flow, extend filter life, and provide flexibility for patients of varying sizes.

Technology and Clinical Application

The patented Dual Lumen Catheter is specifically engineered for use in extracorporeal therapies, including continuous renal replacement therapy (CRRT). A key feature of the design is its ability to allow clinicians to trim the catheter to an appropriate length for individual patients without compromising structural integrity. This customization capability aims to enhance therapy performance by ensuring the device remains resistant to collapse while fitting diverse patient anatomies.

Strategic Impact

Nuwellis’ CEO Mike McCormick emphasized that effective vascular access is fundamental to the performance of extracorporeal therapies. He stated that the patent reflects the company's commitment to developing practical innovations for real-world clinical challenges. By combining resistance to collapse with customizable length, the technology seeks to provide clinicians with greater flexibility across a broad range of patient populations. The issuance of this patent supports Nuwellis' broader strategy of advancing differentiated technologies across the heart-kidney continuum.

Nuwellis has installed three Aquadex SmartFlow Systems at a pediatric healthcare provider in Michigan, marking its first pediatric program in the state. This installation expands Nuwellis' growing presence in pediatric critical care into a significant healthcare market. The systems are designed to provide controlled, predictable fluid removal for patients suffering from fluid overload, a critical need in pediatric care settings.

The new installations support the development of clinical protocols and workflows to integrate Aquadex therapy into the hospital's pediatric care program. This integration creates a foundation for future consumable utilization and long-term growth. Clinicians are increasingly adopting Aquadex therapy in pediatric and critical care settings, highlighting its strategic importance for Nuwellis.

Pediatric programs represent a key growth opportunity for Nuwellis to broaden access to Aquadex therapy. By expanding into this segment, the company aims to strengthen its leadership position in the fluid management category. The Michigan installation is part of Nuwellis' broader strategy to prioritize expansion within pediatric and critical care markets.

The Aquadex SmartFlow System is a critical tool for managing fluid overload in pediatric patients. Its adoption underscores the growing demand for advanced fluid management solutions in specialized care environments. Nuwellis' focus on pediatric programs aligns with its mission to improve patient outcomes through innovative therapy options.